Homology Medicines Stock Shares Owned By Insiders
| FIXXDelisted Stock | USD 1.09 0.06 5.83% |
Homology Medicines fundamentals help investors to digest information that contributes to Homology Medicines' financial success or failures. It also enables traders to predict the movement of Homology Stock. The fundamental analysis module provides a way to measure Homology Medicines' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Homology Medicines stock.
Homology |
Homology Medicines Company Shares Owned By Insiders Analysis
Homology Medicines' Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
More About Shares Owned By Insiders | All Equity Analysis
Insiders Shares | = | Executives Shares | + | Employees |
Current Homology Medicines Shares Owned By Insiders | 9.20 % |
Most of Homology Medicines' fundamental indicators, such as Shares Owned By Insiders, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Homology Medicines is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
CompetitionBased on the latest financial disclosure, 9.2% of Homology Medicines are shares owned by insiders. This is 39.39% lower than that of the Biotechnology sector and 35.12% lower than that of the Health Care industry. The shares owned by insiders for all United States stocks is 8.82% higher than that of the company.
Homology Shares Owned By Insiders Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Homology Medicines' direct or indirect competition against its Shares Owned By Insiders to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Homology Medicines could also be used in its relative valuation, which is a method of valuing Homology Medicines by comparing valuation metrics of similar companies.Homology Medicines is currently under evaluation in shares owned by insiders category among its peers.
Homology Fundamentals
| Return On Equity | -0.9 | |||
| Return On Asset | -0.36 | |||
| Operating Margin | (78.85) % | |||
| Current Valuation | (27 M) | |||
| Shares Outstanding | 3.23 M | |||
| Shares Owned By Insiders | 9.20 % | |||
| Shares Owned By Institutions | 46.75 % | |||
| Number Of Shares Shorted | 338.72 K | |||
| Price To Earning | (10.00) X | |||
| Price To Book | 0.04 X | |||
| Price To Sales | 2.61 X | |||
| Revenue | 1.16 M | |||
| Gross Profit | (95.14 M) | |||
| EBITDA | (91.52 M) | |||
| Net Income | (112.96 M) | |||
| Cash And Equivalents | 201.07 M | |||
| Cash Per Share | 3.50 X | |||
| Total Debt | 1.32 M | |||
| Debt To Equity | 0.14 % | |||
| Current Ratio | 8.44 X | |||
| Book Value Per Share | 22.65 X | |||
| Cash Flow From Operations | (96.23 M) | |||
| Short Ratio | 0.62 X | |||
| Earnings Per Share | (35.10) X | |||
| Price To Earnings To Growth | 21.38 X | |||
| Target Price | 1.5 | |||
| Beta | -0.11 | |||
| Market Capitalization | 3.02 M | |||
| Total Asset | 306.12 M | |||
| Retained Earnings | (542.1 M) | |||
| Working Capital | 72.34 M | |||
| Current Asset | 48.82 M | |||
| Current Liabilities | 8.27 M | |||
| Net Asset | 306.12 M |
About Homology Medicines Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Homology Medicines's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Homology Medicines using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Homology Medicines based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Other Consideration for investing in Homology Stock
If you are still planning to invest in Homology Medicines check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Homology Medicines' history and understand the potential risks before investing.
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing |